The State Drug Administration approves Sanofio Batiere ® (Trifluoroamine tablet) to be listed in China
-
Last Update: 2020-06-11
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Sanofi China announced that the NationalMedicines(the Supervisory Authority has recently approved the ® of Aubameyang (Trifluoramine tablets) to be available in China for the treatment of recurrent multiple sclerosisfour randomized, controlled, double-blind clinicaltrial(determines the efficacy of the Obatier ® in patients with recurrent multiple sclerosis, data from two Phase III clinical studies, the TEMSO study and the TOWER study, showed that in the core phase study, the ® significantly reduced the annual recurrence rate of patients compared to placebo, but also delayed the progression of disability, and maintained efficacy for up to 10 years 3,4 in the extended studyIn the TOWER study, the annual recurrence rate of patients in the Chinese subgroup of the Obatier ® 14mg treatment group decreased the relative risk of recurrence by 71.2%, while the relative risk of relapse in the global patients in the same group decreased by 36.3%The ® of Aubameyang has been approved in more than 70 countries and territories around the world, and more than 85,000 multiple sclerosis patients are currently receiving treatment
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
